Literature DB >> 25527567

Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.

Wei-Gang Tong1, Vicky K Sandhu2, Brent L Wood3, Paul C Hendrie4, Pamela S Becker4, John M Pagel4, Roland B Walter4, Elihu H Estey5.   

Abstract

Entities:  

Keywords:  FLT3-ITD; NPM1; acute myeloid leukemia; mutations; peripheral blood bone marrow

Mesh：

Substances：

Year:  2014        PMID： 25527567      PMCID： PMC4349287          DOI： 10.3324/haematol.2014.118422

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

Review 1.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

2.  Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.

Authors:  R Weinkauff; E H Estey; P Starostik; K Hayes; Y O Huh; C Hirsch-Ginsberg; M Andreeff; M Keating; H M Kantarjian; E J Freireich; M Albitar
Journal:  Am J Clin Pathol       Date:  1999-06       Impact factor: 2.493

3.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

4.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

5.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Authors:  Richard F Schlenk; Konstanze Döhner; Jürgen Krauter; Stefan Fröhling; Andrea Corbacioglu; Lars Bullinger; Marianne Habdank; Daniela Späth; Michael Morgan; Axel Benner; Brigitte Schlegelberger; Gerhard Heil; Arnold Ganser; Hartmut Döhner
Journal:  N Engl J Med       Date:  2008-05-01       Impact factor: 91.245

Review 6.  The importance of molecular monitoring in acute promyelocytic leukaemia.

Authors:  Francesco Lo-Coco; Massimo Breccia; Daniela Diverio
Journal:  Best Pract Res Clin Haematol       Date:  2003-09       Impact factor: 3.020

Review 7.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

8.  Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.

Authors:  I Jilani; E Estey; T Manshuri; M Caligiuri; M Keating; F Giles; D Thomas; H Kantarjian; M Albitar
Journal:  Leukemia       Date:  2003-01       Impact factor: 11.528

9.  Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis.

Authors:  Kebede Hussein; Rhett P Ketterling; Rachael L Hulshizer; Daniel G Kuffel; Anne E Wiktor; Curtis A Hanson; Ayalew Tefferi; Daniel L Van Dyke
Journal:  Eur J Haematol       Date:  2007-12-18       Impact factor: 2.997

10.  Circulating tumor DNA moves further into the spotlight.

Authors:  Mark Sausen; Sonya Parpart; Luis A Diaz
Journal:  Genome Med       Date:  2014-05-28       Impact factor: 11.117
  10 in total
  7 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Authors:  Eric J Duncavage; Geoffrey L Uy; Allegra A Petti; Christopher A Miller; Yi-Shan Lee; Bevan Tandon; Feng Gao; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Meagan A Jacoby; Amanda F Cashen; Lukas D Wartman; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley; John S Welch
Journal:  Blood       Date:  2017-01-12       Impact factor: 22.113

3.  Acute myeloid leukemia therapy and the chosen people.

Authors:  E Estey; R P Gale
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

4.  Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.

Authors:  Daniel H Albert; Neal C Goodwin; Angela M Davies; Jenny Rowe; Gerold Feuer; Michael Boyiadzis; Kathleen A Dorritie; Maria Mancini; Regina Gandour-Edwards; Brian A Jonas; Gautam Borthakur; Ibrahim Aldoss; David A Rizzieri; Olatoyosi Odenike; Thomas Prebet; Sanjana Singh; Relja Popovic; Y U Shen; Keith F McDaniel; Warren M Kati; Dimple A Modi; Monica Motwani; Johannes E Wolff; David J Frost
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

5.  Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Authors:  Samaneh Sadat Seyyedi; Masoud Soleimani; Marjan Yaghmaie; Monireh Ajami; Mansoureh Ajami; Shahram Pourbeyranvand; Kamran Alimoghaddam; Seyed Mohammad Akrami
Journal:  Tumour Biol       Date:  2015-11-02

6.  AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

Authors:  Era L Pogosova-Agadjanyan; Anna Moseley; Megan Othus; Frederick R Appelbaum; Thomas R Chauncey; I-Ming L Chen; Harry P Erba; John E Godwin; Isaac C Jenkins; Min Fang; Mike Huynh; Kenneth J Kopecky; Alan F List; Jasmine Naru; Jerald P Radich; Emily Stevens; Brooke E Willborg; Cheryl L Willman; Brent L Wood; Qing Zhang; Soheil Meshinchi; Derek L Stirewalt
Journal:  Biomark Res       Date:  2020-08-12

7.  Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Authors:  Hong Yuen Wong; Anthony D Sung; Katherine E Lindblad; Sheenu Sheela; Gregory W Roloff; David Rizzieri; Meghali Goswami; Matthew P Mulé; Nestor R Ramos; Jingrong Tang; Julie Thompson; Christin B DeStefano; Kristi Romero; Laura W Dillon; Dong-Yun Kim; Catherine Lai; Christopher S Hourigan
Journal:  Front Oncol       Date:  2019-01-15       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.